Another important issue when using antibodies targeting EpCAM is that the expression of this protein may vary in tumor cells during disease progression [41], and expression can be down-regulated as a consequence of epithelial-to-mesenchymal transition (EMT) [42]. This evidence concerns the gene EPCAM and neoplasm.